A truncated direction of glecaprevir-pibrentasvir (Mavyret) prophylaxis started prior to transplant allowed patients without hepatitis C virus (HCV) infection to safely bag kidneys from HCV-particular donors, a small single-center seek stumbled on.
In all, 10 transplants from HCV-particular donors to HCV-detrimental recipients (HCV D+/R-) were performed, and viral RNA grow to be undetectable in all recipients initiating at 7 days put up-transplant and remained so via 12 weeks of practice-up, reported Niraj Desai, MD, and colleagues from Johns Hopkins College in Baltimore in Annals of Internal Medication.
All patients got their first dose of the yell-active antiviral (DAA) about a hours sooner than organ perfusion, then one dose day-to-day for 4 weeks, and no medicines-associated unfavorable occasions or enormous liver enzyme abnormalities were noticed correct via practice-up.
“The dose grow to be absorbed by the liver sooner than the infection, and we noticed very low viral hundreds after transplant,” Desai acknowledged. “Our next step is to additional shorten the medicine direction to 2 weeks.”
Desai advised MedPage This day that other stories on this establish have extinct a transmit-and-contend with reach, initiating antiviral medicines about a days or even about a weeks after transplanting HCV-particular kidneys, which commits the affected person to a paunchy 12-week regimen owing to the enchancment of high viral hundreds.
He renowned that upwards of 500 in any other case transplant-viable kidneys are discarded every year in the U.S. due to HCV-positivity and for lack of very most attention-grabbing HCV-particular recipients. Viremic kidneys offer one other offer of organs and will decrease wait cases to transplant, he acknowledged.
“This seek adds additional to the mounting proof for the safety and efficacy of a prophylactic reach to medicines of HCV in uninfected recipients of HCV-infected donor kidneys,” Raymond Chung, MD, of Massachusetts Regular Clinic in Boston, advised MedPage This day. “They additionally suggest that a DAA regimen as temporary as 4 weeks suffices to forestall allograft infection.”
Chung, who grow to be no longer concerned referring to the present trial, no longer too long in the past participated in a multicenter 30-affected person seek of 8 weeks of glecaprevir-pibrentasvir delivered on day 3 after kidney transplantation with horny outcomes.
“A prophylactic reach begun sooner than the virus has infected the recipient liver could perchance also allow truncation of the direction of antiviral remedy,” Chung added. “Here’s a shining reach, because it minimizes the likelihood of exposure of the affected person to HCV infection.”
The effectiveness of the preemptive reach grow to be confirmed in one other current seek of eight HCV D+/R- kidney transplants. And in thoracic grafts, 4 weeks of put up-exposure prophylaxis with sofosbuvir/velpatasvir (Epclusa) successfully shunned infection in 44 HCV D+/R- coronary heart and lung transplants.
The initiate-mark seek from Desai and colleagues — dubbed REHANNA (Renal Transplants in Hepatitis C Adverse Recipients With RNA Clear Donors) — investigated 4-week prophylaxis with the pangenotypic combination of glecaprevir 300 mg and pibrentasvir 120 mg. No DAA medicines grow to be extinct on the kidney itself.
The transplants were performed in seven men and three females at Johns Hopkins from 2018 to 2019. HCV RNA (lower limit of quantification <15 IU/mL) grow to be measured on postoperative days 1 and 4; at prophylaxis weeks 1, 2, and 4; and at put up-prophylaxis practice-up weeks 1, 4, 8, and 12.
The 10 recipients ranged in age from 45 to 75 years (median 67), and 7 were white.
As for the 10 donors, they ranged in age from 20 to 45 (median 38.5), and their median HCV RNA level grow to be 377,500 IU/mL (19 to 12,900,000 IU/mL). By reach of HCV genotype, six donors had 1a, one had 1b, two had 3, and one had an undetermined genotype.
No put up-transplant deaths came about correct via the median 12 months practice-up (fluctuate 7.4-12). No recipient experienced grade 3 or higher medicines-associated unfavorable occasions or aminotransferase or bilirubin ranges 2.5 cases the higher limit of typical or extra at any time point. At week 12, median estimated glomerular filtration rate grow to be 54.5 mL/min/1.73 m2 (30 to 79 mL/min/1.73 m2). One graft failed at day 261 owing to venous thrombosis unrelated to HCV or medicines, but no rejection episodes came about.
Other researchers have stumbled on the same infection medicines rates and renal diagram ranges with DAA medicines of recipients receiving kidneys from viremic donors, and prophylactic DAA medicines has additionally been stumbled on to salvage livers from HCV-particular donors that will in any other case have been discarded.
Desai’s crew is now planning to test an even shorter medicines direction apart from to a randomized trial to study prophylaxis with the transmit-and-contend with reach.
The authors acknowledged that the small sample measurement restricted generalizability and could perchance honest no longer have identified uncommon risks such because the emergence of resistance.
Disclosures
Desai reported toughen from AbbVie and Merck outside the submitted work.
Coauthors reported relationships with Abbvie, GlaxoSmithKline, Gilead, Arbutus, Assembly Biosciences, Biomarin, Immunocore, Janssen, Clinical Care Alternate strategies, ViralEd, Observe Level, and the Nationwide Institutes of Health.
Chung disclosed toughen from AbbVie, Gilead, and Merck.
